This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.
This site uses cookies. Find out more
Epilepsy affects more than 50 million people worldwide – impacting at least six million in Europe. The condition is generally manageable with pharmacotherapy, with which many people with epilepsy...
A group of epilepsy specialist clinicians gathered to discuss the pharmacological management of focal epilepsy and the potential role of eslicarbazepine acetate (Zebinix). The meeting was organised...
Primary generalised tonic-clonic (PGTC) seizures are the most frequent and disabling seizure type among patientswith idiopathic generalised epilepsy. Uncontrolled seizures are associated with high...
Perampanel is a long-acting novel antiepileptic drug (AED) with a unique mechanism of action targeting the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor. Perampanel’s...
Correct classification of the epilepsy type after the first generalised tonic-clonic (GTC) seizure is important for the choice of treatment. There is a high disease burden with uncontrolled GTC...
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder that can cause non-invasive hamartomatous lesions of any number and size in almost every organ, but are most commonly...
Increasing awareness of Niemann-Pick type C (NP-C) was the focus of the Actelion-sponsored satellite symposium ‘One diagnosis, three presentations, many lives: a biography of Niemann-Pick type C...
Alzheimer’s disease (AD) is associated with progressive deterioration of cognitive and functional abilities (Fig. 1). To date, there is no cure and no validated disease-modifying treatment....